CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- 20 May 2011
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15), e443-e445
- https://doi.org/10.1200/jco.2010.34.1313
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR MutationsJournal of Thoracic Oncology, 2010
- Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.Journal of Clinical Oncology, 2010
- High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancerJournal of Neuro-Oncology, 2010
- Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerNew England Journal of Medicine, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMolecular Cancer Therapeutics, 2007
- Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose GefitinibJournal of Clinical Oncology, 2006
- Pharmacokinetic Considerations in the Treatment of CNS TumoursClinical Pharmacokinetics, 2006
- Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human PrimatesJournal of Neuro-Oncology, 2003